Condition: Gastroesophageal Junction Adenocarcinoma · Esophagogastric Cancer · Sponsor: Massachusetts General Hospital
In this research study, is studying how Liposomal Irinotecan in combination with the standard of care interventions FOLFOX, carboplatin paclitaxel, and radiation therapy affect gastroesophageal junction or esophagogastric cancer This research study involves the following study intervention: \- Liposomal irinotecan
This description comes directly from the study's public registry record.
Jennifer Wo, MD · (617) 726-6050 · JWO@mgh.harvard.edu
Always discuss trial participation with your own doctor first.
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Beth-Israel Deaconess Medical Center | Boston, Massachusetts, United States | Not Yet Recruiting |
| Massachusetts General Hospital at Newton Wellesley Hospital | Newton, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04656041